Chemed Corporation (NYSE:CHE) Receives Average Rating of “Hold” from Analysts

Shares of Chemed Corporation (NYSE:CHE) have been given an average rating of “Hold” by the six brokerages that are covering the company, Marketbeat.com reports. Five investment analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $530.75.

Several analysts have weighed in on CHE shares. Oppenheimer lifted their price objective on shares of Chemed from $500.00 to $590.00 and gave the stock an “outperform” rating in a research note on Friday. Royal Bank Of Canada increased their price objective on shares of Chemed from $436.00 to $548.00 and gave the stock a “sector perform” rating in a research note on Thursday. Wall Street Zen raised shares of Chemed from a “hold” rating to a “strong-buy” rating in a report on Saturday. Zacks Research raised Chemed from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Finally, Weiss Ratings raised shares of Chemed from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, July 17th.

Chemed Price Performance

Shares of NYSE CHE opened at $540.89 on Thursday. The stock has a market capitalization of $7.18 billion, a price-to-earnings ratio of 27.17, a PEG ratio of 2.02 and a beta of 0.51. The business has a 50-day moving average of $469.13 and a 200-day moving average of $437.15. The company has a debt-to-equity ratio of 0.17, a current ratio of 0.91 and a quick ratio of 0.89. Chemed has a fifty-two week low of $365.20 and a fifty-two week high of $551.68.

Chemed (NYSE:CHE) last released its earnings results on Tuesday, July 28th. The company reported $6.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.60 by $0.46. The business had revenue of $673.25 million for the quarter, compared to analyst estimates of $665.04 million. Chemed had a return on equity of 31.77% and a net margin of 10.60%.Chemed’s revenue was up 8.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $4.27 earnings per share. Chemed has set its FY 2026 guidance at 25.000-25.750 EPS. As a group, sell-side analysts predict that Chemed will post 23.18 earnings per share for the current fiscal year.

Chemed Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 16th. Stockholders of record on Thursday, May 28th were issued a $0.60 dividend. The ex-dividend date of this dividend was Thursday, May 28th. This represents a $2.40 annualized dividend and a dividend yield of 0.4%. Chemed’s dividend payout ratio is currently 12.05%.

Insider Transactions at Chemed

In other Chemed news, Director Patrick P. Grace sold 190 shares of the company’s stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $532.00, for a total value of $101,080.00. Following the transaction, the director directly owned 3,533 shares in the company, valued at $1,879,556. This represents a 5.10% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Andrea R. Lindell sold 1,347 shares of the business’s stock in a transaction on Tuesday, June 9th. The shares were sold at an average price of $447.33, for a total transaction of $602,553.51. Following the sale, the director owned 4,578 shares in the company, valued at approximately $2,047,876.74. This trade represents a 22.73% decrease in their position. The disclosure for this sale is available in the SEC filing. 3.33% of the stock is owned by company insiders.

Institutional Trading of Chemed

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Geneos Wealth Management Inc. boosted its position in Chemed by 330.4% in the first quarter. Geneos Wealth Management Inc. now owns 99 shares of the company’s stock valued at $61,000 after buying an additional 76 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its stake in shares of Chemed by 67.0% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 11,365 shares of the company’s stock valued at $5,534,000 after buying an additional 4,560 shares during the last quarter. Marshall Wace LLP acquired a new position in shares of Chemed in the 2nd quarter valued at about $579,000. Brown Advisory Inc. boosted its stake in shares of Chemed by 36.9% in the second quarter. Brown Advisory Inc. now owns 549 shares of the company’s stock worth $267,000 after buying an additional 148 shares during the last quarter. Finally, Cerity Partners LLC boosted its stake in shares of Chemed by 237.7% in the second quarter. Cerity Partners LLC now owns 4,451 shares of the company’s stock worth $2,165,000 after buying an additional 3,133 shares during the last quarter. Institutional investors own 95.85% of the company’s stock.

Chemed Company Profile

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.